**Core Concept**
The patient is likely suffering from a chronic inflammatory bowel disease (IBD) characterized by bloody diarrhea, with sulfasalazine being an inadequate treatment option, and steroids used for flare control. This clinical presentation points towards a diagnosis of Ulcerative Colitis (UC), a type of IBD.

**Why the Correct Answer is Right**
The patient's inadequate response to sulfasalazine, a 5-aminosalicylic acid (5-ASA) agent, and requirement for steroids during flares, indicates a more severe disease course. Azathioprine, an immunomodulator, is often considered as a next-line treatment in patients with moderate to severe UC who have failed to respond to or are dependent on steroids. Azathioprine works by inhibiting the enzyme xanthine oxidase, which in turn reduces the levels of the purine nucleotide, inosine monophosphate (IMP), thereby decreasing the proliferation of T and B lymphocytes.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect as there is no mention of the patient's disease being limited to the rectum, which would be the case in proctitis, a mild form of UC. Azathioprine is not used as a first-line treatment for proctitis.
* **Option B:** This option is incorrect as the patient has not been adequately treated with a 5-ASA agent, such as mesalamine, which is the preferred first-line treatment for mild to moderate UC. Azathioprine is not used as a first-line treatment in this scenario.
* **Option C:** This option is incorrect as the patient has not been treated with a biologic agent, such as infliximab, which is a TNF-alpha inhibitor. Biologics are typically used as a next-line treatment in patients with moderate to severe UC who have failed to respond to or are dependent on immunomodulators like azathioprine.

**Clinical Pearl / High-Yield Fact**
It is essential to note that the treatment of UC should be tailored to the individual patient's disease severity, symptoms, and response to therapy. A step-up approach, starting with 5-ASA agents, followed by immunomodulators, and finally biologics, is often used to manage UC.

**Correct Answer:** C.